Regencell Bioscience Holdings Limited's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026The company is raising cash by selling new shares, which dilutes existing shareholders but provides funds for operations or growth.
The company can now sell shares gradually at market prices when needed, giving it flexibility to raise cash without a fixed sale date.
Stocky reads Regencell Bioscience Holdings Limited's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Regencell Bioscience Holdings Limited's most recent tracked filing was a 424B5 on 19 May 2026: Sells 985,222 shares at $20.30 per share via placement agent.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.